None listed
Conditions
Interventions
None listed
Sponsors
National Biopharma Mission, BIRAC, Department of Biotechnology â?? Government of India
Eligibility
Inclusion criteria
Inclusion criteria: Study will be carried out in individuals above 2 Years of age. Individuals currently residing and likely to stay till the end of one year in the study area. Consented to participate in both sections of the study (Sero Prevalence and AFI Surveillance) and follow all procedures.
Exclusion criteria
Exclusion criteria: Ongoing fever episodes or history of AFI on or within 3 calendar days before enrolment for the cohort
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proposed study is expected to determine a. Incidence rate of acute febrile illness episode during 12 months of follow up b. Incidence rate of symptomatic laboratory confirmed Dengue infection episodes during 12 months of follow up c. Incidence of Sero positivity based on IgG, IgM & neutralizing antibodies at 12 months (Sero Negative for IgG, IgM or Neutralizing antibodies at baseline at enrolment).Timepoint: Objective Expected Timelines Establishment of Cohort 1 â?? 2 Months Base Line Sero-prevalence 1-2 Months Incidence of acute febrile illness 12 â?? 13 Months Sero Incidence of IgG, IgM & Neutralizing antibodies 13 Months Reporting & Submission of result 14 â?? 15 months | — |
Secondary
| Measure | Time frame |
|---|---|
| The proposed study will determine 1. Incidence rate of symptomatic laboratory confirmed Chikungunya infection episodes during 12 months of follow up 2. Determine the etiology of AFI due to other common causes of AFI (based on rapid diagnostic or ELISA based laboratory diagnosis) a. Malaria b. Scrub typhus c. Leptospirosis d. Typhoid 3. Describe the proportion of symptomatic versus asymptomatic or sub clinical infections of dengue and Chikungunya based on data obtained from primary objectives. 4. Identify & describe the circulating serotypes of dengue & chikungunya in the general population over a period of one year. 5. To assess spatiotemporal trend of Dengue & Chikungunya infection over a period of 12 months. 6. Determine the durability of IgG, IgM & Neutralizing antibodies in symptomatic individuals tested n Positive for Dengue and Chikungunya infection. Timepoint: Establishment of Cohort 1 â?? 2 Months Base Line Sero-prevalence 1-2 Months Incidence of acute febrile illness including lab confirmed Malaria, Scrub typhus, Leptospirosis & Typhoid 12 â?? 13 Months Sero Incidence of IgG, IgM & Neutralizing antibodies 13 Months Identification of circulating serotype of Dengue & Chikungunya 13 Months Analysis of spatiotemporal trend of Dengue and Chikungunya 13 Months Durability of Antibodies 13 Months | — |
Countries
India
Contacts
Public ContactDr Saranya R
Pondicherry Institute of Medical Sciences
Outcome results
None listed